chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Approximately 15 minutes after receiving vaccine, patient became dizzy at the office check out desk. SHe had a syncope episode. Her mother caught her and she did not hit her head on floor or wall. 8/28/2015 patient back in office complaining of headache on and off and dizziness since episode on 8/26. Physical and neurological exam performed. He diagnosed patient with vertigo and prescribed Meclizine. Labs were drawn and EKG ordered. 9/3/2015 Patient returned to office still complaining of dizziness. This day she was seen again by another doctor...she agreed with diagnosis of vertigo. Additonal labs ran. 9/8/2015 Mom reports patient is back to normal.
*Body aches  *headache  *Severe  muscle pain  *Inflamed lymphnode *Chills
I had a fever and chills, aches all over but especially in the joints of hips, knees, ankles, feet.   When I was able to get out of bed to take my temperature is was 99.4F - this was after I felt a little better so it may have been higher during  the night.  My temperature usually runs 97.5F
This spontaneous report was received from a registered nurse refers to an unspecified number of patients of unknown age and gender. No pertinent medical history was reported. On an unknown date, the patients was vaccinated with improperly stored doses of PROQUAD (Merck) (strength, dose, route, lot # were not reported). No Product Quality Complaint (PQC) was involved. This is one of the two reports from the same source. Additional information has been requested.
This spontaneous report was received from a nurse referring to multiple unspecified patients of unknown age and gender. Pertinent medical histories, drug reactions or allergies and concomitant therapies were not reported. On unspecified dates after 24-MAR-2015, the patients were vaccinated with improperly stored doses of Gardasil (lot # K006447 with an expiry date 19-JUN-2016, doses, frequencies and route were not reported). No adverse effects were reported. It was reported that vaccines were not discontinued. There was no product quality complaint (PQC) involved. This is one of several reports received from the same reporter. Additional information has been requested.
A report had been received from a health professional concerning a 2 year old female patient. The medical history and the concomitant medications were not reported. The patient received FLUMIST quadrivalent (intranasal) on an unknown date. The reporter stated that the patient had flu like symptoms after receiving FLUMIST quadrivalent. The symptoms included wheezing, runny nose, irritability, body aches, and fever of 101.7 while taking ibuprofen. The patient received FLUMIST on 18-Oct-2013 and symptoms started on 20-Oct-2013. The physician of the patient was aware, but reporter did not have physician information. The outcome of the event of patient had flu like symptoms after receiving FLUMIST quadrivalent, wheezing, runny nose, irritability, body aches and fever of 101.7 is unknown.
Day 0 after injection my daughter's body was having slight seizures. Got worse until hospitalized. Up to 20 seizures a day for 10 days. Checked into hospital. Diagnosis epilepsy.
Approximately 1 week after she was ill.  Had cough, hand tingling and numbness bi-laterally.  Progressed into what appeared to be stroke-like symptoms.  Still experiencing neurological issues; including tightness in face, eyes and hands.   Neck jerking and other uncontrollable movements by eyes and face.
25 PATIENTS GIVEN THE JANSSEN  COVID-19 VACCINE PAST THE  EXPIRATION DATE; This spontaneous report received from a health care professional concerned multiple patients. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1821286, expiry: 21-OCT-2021) dose was not reported, administered on OCT-2021 for prophylactic vaccination. No concomitant medications were reported. On OCT-2021, the patient experienced 25 subjects given the janssen covid-19 vaccine past the expiration date. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of 25 patients given the janssen covid-19 vaccine past the expiration date was not reported. This report was non-serious.
Heart attack; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of MYOCARDIAL INFARCTION (Heart attack) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYOCARDIAL INFARCTION (Heart attack) (seriousness criterion medically significant). At the time of the report, MYOCARDIAL INFARCTION (Heart attack) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Treatment information was not provided.; Sender's Comments: Very limited information regarding the event, Myocardial infarction, has been provided at this time. There is no patient information, no onset date and on outcome of the event. No patient information to further follow-up.  This case was submitted via adverse event chatbot Text.
11:30 AM Given Hep A, HPV and Influenza vaccines. Within +/-10 seconds of receiving the influenza vaccine, patient experienced shaking of hands, 3-5 seconds of confusion, and fell back on exam table into Medical Assistant's arms. 1 minute after symptoms, patient was placed on her back with legs elevated. ARNP examined pt. and vital signs were done. Vitals were within normal limits. Neurological exam was unremarkable. Pupils were equal and reactive to light bilaterally. Due to patient's past medical history of seizures (last episode age 4 years), Pediatrician was called and instructions were received to send her to the Emergency Room for evaluation of vasovagal episode.
Initial report received 29 April 2008 from a health care professional. A seven-year-old female patient had received an intramuscular left deltoid injection of FLUZONE, lot number U2440AA (0.5mL) on 31 October 2007 and immediately following vaccination. a black dot appeared at the injection site. According to the reporter, the recovery status of the patient was unknown at the time of the report. The reporter received a cluster of reports of black dots at the injection site from multiple satellite locations who were all affiliated with the reporter. The facilities used McKesson alcohol wipes and syringes which included safety glide and vanish point with 25 gauge needles. Some of the black dots were reported to have appeared immediately with some present two months post immunization. This event had been noticed by all health care worker at the facilities and had not been noticed in the past. The reporter indicated follow-up information would be provided as it is obtained. The reporter for this case is the same as for case number 2008-01333 (IPOL and ActHIB), 2008-01334 (IPOL), 2008-01335 (IPOL), 2008-01336 (IPOL and DTaP) and 2008-01339 (IPOL). These events occurred at multiple satellite locations which are all affiliated with the reporter.
This is in follow-up to report(s) previously submitted on 9/14/2008. Information has been received from a physician assistant concerning a 14 year old female with attention deficit/hyperactivity disorder and no known allergies, who on 30-Aug-2007 was vaccinated with the first dose of GARDASIL (Lot No. 658094/0524U) into the left deltoid, and on 13-Feb-2008 was vaccinated with second doses of GARDASIL (Lot No. 858282/0929U) into the right deltoid and on 17-JUL-2008 was vaccinated with the third dose of GARDASIL (Lot No. 660389/1968U) into the left deltoid. Concomitant therapy included FOCALIN 30 mg morning, and RESPERDAL (reported as "RESPIDERAL") 20mg morning. Unspecified medical attention was sought. Patient developed multiple warts on her hand an one on her foot after starting the GARDASIL series. It was reported that on 16-Jul-2008 (date reported as "yesterday") the patient was seen by a physician assistant and she had 15 warts on her left hand, 7 warts on her right hand and 1 wart on her left foot. It was reported that the patient had never had any warts before, and will be seen for follow up visit.  At the time of this report the patient had not recovered from her experience. No additional information is expected.
c/o generalized rash which devel following day; pt tried treating self for pruritus w/OTC body powder, w/no improvement; presents w/generalized maculo-papular eruption-etiology unk;
Within 2 minutes of receiving vaccine funny sensation in my mouth Very mild Only lasted few minutes never reported. Within 1 hour of receiving the vaccine numbness tip of my tongue. At around 0630 started with restlessness, sob, coughing which kept getting worse, stated losing my voice. Went to urgent care and given injection of solumedrol, and back to back doses of duo neb treatments Released. At 0400 next day started again with SOB, coughing, Resolved with duoneb treatment 4 to 5 hours later started again with SOB and coughing  Resolved with duoneb treatment. No further episodes
The lot number for the first dose of vaccine taken on 01/20/2021 is: FL3246. And the lot number for the second dose of the vaccine taken on 02/12/2021 is :EN6200. Within 7 to 10 days beginning in early April of 2021, My hear texture changed and my head became very itchy and inflamed. I have been to a couple of doctors and have been diagnosed with a rare skin disease called lichen planopilaris which is an auto immune response that caused scarring of the scalp and loss of hair.
#1:  01/22/2021 Pfizer       Lot# EL1283     Dose: 0.3ml #2:  02/11/2021 Pfizer       Lot# EL9269     Dose: 0.3ml #3:  03/18/2021 Moderna  Lot# 045A21A  Dose: 0.5ml #4.  04/20/2021 Moderna  Lot# 044B21A  Dose: 0.5ml #5.  09/21/2021 Pfizer       Lot# FE3592     Dose: 0.3ml  #6.  04/26/2022 Pfizer       Lot# FJ1611      Dose: 0.3ml There were 6 Covid vaccinations given from 1/22/21-4/26/22. The last vaccination was given at a vaccination site at a mobile event.
c/o pain lt arm 24 hrs p/vax administered; mom noted sl redness, swelling; @ 48 hrs mom reported lt arm was swollen to elbow @ warm; 21JUN93 pt was seen by MD;
Information has been received from a physician via a company representative referring to a 49 year old patient of unknown gender. On an unknown date the physician administered a dose of ZOSTAVAX (dose, route, lot # and expiration date unknown) to the patient. No adverse effects were reported. Additional information is not expected since we have no consent to contact the physician.
Menstrual cycle was 50 days late 104 degree fever and severe body aches for 48 hours post injection
Patient reported pain and swelling at injection site with radiated to the left side of neck; no fever & seen at ER 5 days ago. Pt placed in sling & given pain medication.
member was given Typhoid at 0915 on 06/06/2009. He had onset of localized pain and discomfort at site. Approximately 1 hour later his pain spread to his joints, chest wall and right upper extremity, hip and knee joints. Pain increased with activity. Member had a history of being bit by a tick 5 days proior with no bullseye leision.
I passed out approximately 14 hours after receiving the vaccine.  I am experiencing a particularly heavy menstrual period simultaneously.  I do not know what caused the syncope, but wanted to report what happened.
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On 09-JAN-2017, the patient was vaccinated with an expired dose of ZOSTAVAX lot # L039094, expiration date 08-JAN-2017 (dose and route of administration were not reported). No adverse effects were reported. Product quality complaint (PQC) was not involved. Additional information is not expected as there is no information available.
lightheaded; BP was taken 3 times: 70/40 @1535; 105/61 @ 1540; 104/77 @1548. Client has hx of syncope with sight of needles, and client stated she ate a light breakfast and lunch.
side affects to their menstrual cycle; blood clots on women while on their periods; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of MENSTRUAL DISORDER (side affects to their menstrual cycle) and HEAVY MENSTRUAL BLEEDING (blood clots on women while on their periods) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MENSTRUAL DISORDER (side affects to their menstrual cycle) and HEAVY MENSTRUAL BLEEDING (blood clots on women while on their periods). At the time of the report, MENSTRUAL DISORDER (side affects to their menstrual cycle) and HEAVY MENSTRUAL BLEEDING (blood clots on women while on their periods) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment medications were reported.
reported that doses of GARDASIL9 had been administered following a temperature excursion; This spontaneous report has been received from a health professional, referring to a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history, concomitant medications, previous drug and/or allergy reactions were not reported.    On 06-AUG-2021, the patient was vaccinated with an improperly stored hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) at a dose of 0.5 milliliter (vaccination scheme, route and anatomical location of administration were not provided; lot # T026167 has been verified to be a valid lot number, and expiration date reported and established upon internal review as 04-DEC-2022) as prophylaxis.   The administered vaccine underwent a temperature excursion below 2 degrees Celsius (°C) of -40.0 °C for a time frame of 15 minutes; and an excursion above 8°C of 9.6 °C for a time frame of 1 hour. No previous temperature excursion was reported. No information about the use of a datalogger was reported.   This is one of several cases, from the same reporter. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T026167; expirationdate: 04-DEC-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet criteria for reportability
Severe local reaction to vaccine treated for possible secondary cellulitis b/c of redness but Most of symptoms were relative to local reaction
Patient received vaccine in arm at clinic. Later in day had red "blotches" on trunk, toe nails became bluish in color. No shortness of breath or lethargy. Mom advised to seek medical thru PCP or local ER.
T78.40XA ALLERGIC REACTION, INIT 4/30/2023 FOREIGN BODY IN ESOPHAGUS, INIT T78.40XD ALLERGIC REACTION, SUBSEQ 5/3/2023 FOREIGN BODY IN ESOPHAGUS, INIT
48 hours after shot MMR, pt with temp 102, fussy, decreased appetite and fluid intake. Seen at office. Child irritable, temp 100.9, not toxic, right OM noted and treated.
Pt. receieved vaccine 12 hours past expiration. No adverse event. MD contacted pt. Pt. declined revaccination
On 3/26 at  2:15 PM starting breaking out with hives on forehead and they became very itchy, and then spread to entire body.  Red hard warm area the size of half-dollar formed at injection site and knot formed. As of 4/23 knot is still palpable and it about the size of a dime and still radiates heat. At 4:00 PM client went to Emergency room for reaction. Client was given H1 & H2 blocker,  Pepcid, Zyrtec, and Benadryl. Was told to apply calamine lotion to the itchy hive areas. She was then told to follow- up with doctor.
This case was reported by a other health professional via other manufacturer and described the occurrence of incorrect storage of drug in a patient who received ENGERIX B (batch number 995J5, expiry date 6th February 2017). On 24th November 2014, the patient received ENGERIX B. On 24th November 2014, an unknown time after receiving ENGERIX B, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown. Additional information: This product has been exposed to temperature outside of the required temperature range and the efficacy of this product outside the temperature range had not been established. No adverse events were reported to the office. Per other health professional at office this product has been administered to several patients, ages and genders are unknown at the time of reporting.
Information has been received from a physician concerning a 22-year-old female patient who on 11-SEP-2008 received the first dose of 0.5 mL GARDASIL (lot number and injection site not reported) via intramuscular route. On an unknown date after the vaccination, the patient developed a rash on her abdomen. No itching was noted. She sought unspecified medical attention through phone call. At the time of reporting, the patient was recovering from the event. Additional information has been requested.
Persistent headache which started night of vaccine, unrelieved with Tylenol, continues today (12/20).  Fatigue which has gotten worse, to today where I struggled to function and had to call in for tonight?s shift at the hospital.
Patient came into the pharmacy on Friday, 10/17/2014 at 11:00am to show the pharmacist on duty her left arm where she had received the Zostavax vaccine subcutaneously a week prior (10/10/2014 at 1:00pm). She said that on Monday, 10/13/14 or Tuesday, 10/14/14 she noticed that the site looked a little red and wasn't sure if she was having a reaction to the vaccine or if it could be caused from having the shingles previously. The pharmacist on duty on 10/17/14 looked at the injection site and noticed it there was a red spot about the size of a quarter with what possibly looked like a small blister underneath. There weren't any signs of swelling, puss, warmth, and the patient said she felt perfectly fine expect the site itched a litte. The pharmacy manager that administered the vaccine called the patient the night of 10/17/2014 and she said that the site wasn't spreading and that she thought the redness was starting to go down. She said she did not feel that she needed to seek medical attention and that she just wanted to continue to monitor it. The pharmacy manager called back on Sunday, 10/19/14 to follow up with the patient and she said that the redness was starting to go away and that it was not itching as much. On Monday, 10/20/2014 the patient said that the redness was almost completely gone and the site really didn't itch anymore and that she thought it was pretty much resolved. The pharmacy manager called the patients Doctor's office and spoke to R.N. to let them know about the possible adverse reaction and they said that they would make note of it and to instruct the patient to be seen if the redness doesn't go away, comes back, or gets worse.
7/30/21: LEFT ANKLE SWELLED UP AND HAD A HEADACHE. SYMPTOMS LASTED 5 DAYS (UNTIL 8/4/21)
This spontaneous report as received from a physician refers to a patient of unknown age and gender. On 07-NOV-2014 the patient was inadvertently administered a partial dose of M-M-R II (exact dose, units, route of administration, anatomical location, lot number were not reported) due to a syringe that leaked during administration. No PQC (product quality complaint). The physician stated that the patient was immediately administered half of a dose from another M-M-R II (exact dose, units, route of administration, anatomical location, lot number were not reported) vial to compensate but the patient may have received more than a full dose altogether. No adverse effects reported. Additional information has been requested.
Pfizer-BioNTech COVID-19 Vaccine EUA: patient hospitalized with COVID-19 pneumonia and acute respiratory failure. Received remdesivir, steroids, and supplemental oxygen. Discharged to home medically stable.
15 -month-old patient received Boostrix; received Boostrix instead of a dTAP in error; This case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 15-month-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 53BF4, expiry date 14th August 2021) for prophylaxis.   On 9th August 2021, the patient received Boostrix (intramuscular). On 9th August 2021, unknown after receiving Boostrix, the patient experienced inappropriate age at vaccine administration and accidental underdose. On an unknown date, the outcome of the inappropriate age at vaccine administration and accidental underdose were unknown.  Additional details were provided are as follows: A 15 months old patient received Boostrix instead of a dTAP  in error, which led to inappropriate age at vaccine administration and accidental underdose. The reporter consented to follow-up.
hives, dizzy, nausea, fainting-this lasted 24 hours -the reaction was 5 days after the vaccine-I did get a B12 mic shot on the Monday after getting vaccine on Friday. Felt fine until Wednesday then broke out in hives and later that day fainted. Still to this day I am breaking out almost every day and I think it is tied to heat. Met with doctor today and she put me on steroid to try to calm down the break outs and then re-evaluate.
This case was reported by a physician via sales rep and described the occurrence of reflex sympathetic dystrophy in a female patient who received SHINGRIX for prophylaxis. Concurrent medical conditions included reflex sympathetic dystrophy. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a day after receiving SHINGRIX, the patient experienced reflex sympathetic dystrophy. On an unknown date, the outcome of the reflex sympathetic dystrophy was not recovered/not resolved. It was unknown if the reporter considered the reflex sympathetic dystrophy to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The physician reported that the patient's preexistent condition of reflex sympathetic dystrophy was greatly exaggerated on the day of the vaccination. Till the time of reporting, the patient still not back to baseline. The information was provided to the MSO (healthcare management service organization) by text message from the physician. No additional details were provided.
pt recvd vax; had difficulty breathing;seen at clinic; 2 episodes of 10-15 secs of apnea,accompanied by extension of arms & head/eye deviation;WBC=36k;
Severe local pain left deltoid @ four hours, with gradual improvement over next 4 weeks. Treated with Ibuprofen.
This spontaneous report was received from a nurse and refers to unspecified patients of unknown age and gender. No information about the patients' pertinent medical history, concurrent conditions, concomitant medications, drug reactions or allergies was provided. On an unknown date, the patients received improperly stored VARIVAX (Merck) (dose, route of administration, lot# and expiration date were not reported). No adverse effects were reported. Additional information has been requested.